Scott David Ramsey

Scott David Ramsey's AcademicInfluence.com Rankings

Scott David Ramsey

Philosophy

#6148

World Rank

#9135

Historical Rank

Logic

#3334

World Rank

#4475

Historical Rank

philosophy Degrees

Scott David Ramsey

Biology

#8315

World Rank

#11372

Historical Rank

Molecular Biology

#1043

World Rank

#1067

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Scott David Ramsey's Degrees

Doctorate Medicine University of Pennsylvania
PhD Molecular Biology University of Pennsylvania

Why Is Scott David Ramsey Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Scott David Ramsey's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. (2004) (2947)
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. (2001) (1137)
Incidence, outcomes, and cost of foot ulcers in patients with diabetes. (1999) (1100)
Early detection: The case for early detection (2003) (703)
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. (2005) (681)
The economic burden of COPD. (2000) (645)
Effect of improved glycemic control on health care costs and utilization. (2001) (543)
Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. (2013) (539)
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. (2016) (502)
Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. (2015) (501)
Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. (2013) (365)
Breast Cancer in Limited‐Resource Countries: An Overview of the Breast Health Global Initiative 2005 Guidelines (2006) (360)
Quality of life in survivors of colorectal carcinoma (2000) (342)
A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. (2010) (280)
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2009) (277)
Why do men choose one treatment over another? (2006) (269)
Cervical spine screening with CT in trauma patients: a cost-effectiveness analysis. (1999) (269)
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. (2012) (238)
Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. (2012) (232)
Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. (2003) (217)
Using Generalized Linear Models to Assess Medical Care Costs (2000) (200)
Quality of life in long term survivors of colorectal cancer (2002) (188)
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. (2014) (185)
Cancer biomarkers: a systems approach (2006) (181)
Breast Cancer in Limited‐Resource Countries: Health Care Systems and Public Policy (2006) (175)
Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. (2007) (168)
Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. (2004) (158)
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. (2010) (151)
Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention (2006) (146)
Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. (2016) (144)
The use of automated data to identify complications and comorbidities of diabetes: a validation study. (1999) (143)
Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. (2011) (140)
Economic burden for informal caregivers of lung and colorectal cancer patients. (2010) (133)
Cost-Effectiveness of Microsatellite Instability Screening as a Method for Detecting Hereditary Nonpolyposis Colorectal Cancer (2001) (133)
The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. (1995) (130)
Economic Evaluation of Aquatic Exercise for Persons With Osteoarthritis (2001) (127)
The Costs of Treating Breast Cancer in the US (2012) (126)
On the use of survival analysis techniques to estimate medical care costs. (1999) (124)
Does Adherence Make a Difference?: Results From a Community-Based Aquatic Exercise Program (2002) (120)
Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. (2012) (114)
The role of hospital volume in coronary artery bypass grafting: is more always better? (2001) (112)
Costs of Pulmonary Rehabilitation and Predictors of Adherence in the National Emphysema Treatment Trial (2008) (111)
Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials (2016) (111)
Primary care physician compensation method in medical groups: does it influence the use and cost of health services for enrollees in managed care organizations? (1998) (109)
Pilot Feasibility Study of an Oncology Financial Navigation Program. (2017) (105)
The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. (2008) (104)
Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6–7, 2011, Arlington, Virginia (2012) (102)
Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. (2016) (101)
Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. (2015) (100)
A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]. (2018) (100)
Use of alternative therapies by older adults with osteoarthritis. (2001) (100)
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. (2004) (99)
A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. (2010) (95)
End-of-life care in the intensive care unit: can we simultaneously increase quality and reduce costs? (2012) (94)
Multi-Modality Mediastinal Staging for Lung Cancer Among Medicare Beneficiaries (2009) (93)
Suboptimal medical therapy in COPD: exploring the causes and consequences. (2000) (93)
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. (2009) (91)
Safety and efficacy of median sternotomy versus video-assisted thoracic surgery for lung volume reduction surgery. (2004) (89)
Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. (2013) (88)
Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials (2018) (87)
Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology. (2008) (86)
A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice (2010) (84)
Improvement in quality of life after lung transplantation: a preliminary study. The University of Washington Medical Center Lung Transplant Study Group. (1995) (83)
Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? (2010) (83)
Clinical and economic effects of pulmonary artery catheterization in nonemergent coronary artery bypass graft surgery. (2000) (83)
Health technology assessment in health-care decisions in the United States. (2009) (83)
Is distance to provider a barrier to care for medicaid patients with breast, colorectal, or lung cancer? (2012) (82)
Randomized trial of amplification strategies. (2001) (82)
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2008) (79)
Cancer Prevention: Obstacles, Challenges and the Road Ahead. (2016) (79)
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. (2016) (79)
Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. (2002) (78)
The burden of illness and economic evaluation for COPD (2003) (76)
An Economic Evaluation of Home Versus Laboratory-Based Diagnosis of Obstructive Sleep Apnea. (2015) (74)
Quality of life in long term survivors of colorectal cancer. (2002) (73)
Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials. (2016) (72)
Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States (2018) (70)
Gene expression profiling and breast cancer care: What are the potential benefits and policy implications? (2005) (69)
Clinical use of medical devices in the 'Bermuda Triangle'. (2004) (69)
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). (2008) (68)
Economic analyses of human genetics services: A systematic review (2005) (63)
Colorectal Cancer Screening with Blood-Based Biomarkers: Cost-Effectiveness of Methylated Septin 9 DNA versus Current Strategies (2013) (60)
AACR Cancer Progress Report 2014 (2014) (60)
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. (2005) (60)
Physiologic Variables and Functional Status Independently Predict COPD Hospitalizations and Emergency Department Visits in Patients with Severe COPD (2007) (59)
The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone. (2016) (58)
Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices (2019) (57)
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. (2009) (56)
Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure. (2016) (55)
Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer. (2013) (54)
Value and affordability of CAR T-cell therapy in the United States (2020) (54)
On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. (2007) (53)
Accounting for Cured Patients in Cost-Effectiveness Analysis. (2017) (53)
Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer (2002) (53)
Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study. (2018) (51)
Design issues for conducting cost-effectiveness analyses alongside clinical trials. (2001) (50)
Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. (2004) (50)
Provider and partner interactions in the treatment decision‐making process for newly diagnosed localized prostate cancer (2011) (50)
Second-line and third-line chemotherapy for lung cancer: use and cost. (2008) (50)
The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer Therapies (2012) (50)
Trends in Treatment Costs for Localized Prostate Cancer: The Healthy Screenee Effect (2007) (49)
The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. (2001) (49)
Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. (2018) (49)
A multifaceted intervention in support of diabetes treatment guidelines: a cont trial. (2002) (49)
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis (2020) (49)
Screening for the Lynch syndrome. (2005) (48)
Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. (2010) (48)
Updated evaluation of the cost-effectiveness of lung volume reduction surgery. (2007) (48)
An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer (2003) (47)
Evaluating the cost‐effectiveness of cancer patient navigation programs: Conceptual and practical issues (2009) (47)
An Economic Evaluation of the JNC Hypertension Guidelines Using Data From a Randomized Controlled Trial (1999) (47)
Addressing the Financial Burden of Cancer Treatment: From Copay to Can't Pay. (2015) (47)
Promoting quality and evidence-based care in early-stage breast cancer follow-up. (2014) (47)
Patient-Level Estimates of the Cost of Complications in Diabetes in a Managed-Care Population (1999) (46)
Community Blood Supply Model: Development of a New Model to Assess the Safety, Sufficiency, and Cost of the Blood Supply (2005) (45)
Chronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular disease. (2006) (45)
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]. (2018) (44)
Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. (2006) (44)
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). (2012) (44)
Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial (2014) (44)
Willingness to pay for antihypertensive care: evidence from a staff-model HMO. (1997) (44)
Preliminary treatment considerations among men with newly diagnosed prostate cancer. (2010) (44)
How should we define value in cancer care? (2010) (43)
Costs and outcomes evaluation of patient navigation after abnormal cancer screening: Evidence from the Patient Navigation Research Program (2014) (43)
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective (2013) (43)
An evaluation of the potential cost‐effectiveness of non‐invasive testing strategies in the diagnosis of significant liver fibrosis (2009) (43)
A controlled time-series trial of clinical reminders: using computerized firm systems to make quality improvement research a routine part of mainstream practice. (2000) (43)
The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. (2016) (43)
Evaluating Frameworks That Provide Value Measures for Health Care Interventions. (2017) (43)
Design, implementation, and first-year outcomes of a value-based drug formulary. (2015) (42)
Evidence, economics, and emphysema: Medicare's long journey with lung volume reduction surgery. (2005) (42)
Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions (2011) (42)
Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. (2006) (40)
Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. (2009) (40)
Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences. (2013) (40)
The limited state of technology assessment for medical devices: facing the issues. (1998) (40)
Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. (2020) (37)
Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer. (2019) (36)
Increased risk of adenomas in individuals with a family history of colorectal cancer: results of a meta-analysis (2010) (36)
Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. (2016) (36)
Moving beyond the national lung screening trial: discussing strategies for implementation of lung cancer screening programs. (2013) (36)
Measuring Costs: Administrative Claims Data, Clinical Trials, and Beyond (2002) (36)
Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics (2013) (36)
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research (2012) (36)
Preference values associated with stage III colon cancer and adjuvant chemotherapy (2010) (35)
Simulation modeling of outcomes and cost effectiveness. (2000) (35)
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. (2013) (35)
Would you like suspenders to go with that belt? An analysis of optimal combinations of cost sharing and managed care. (1999) (35)
The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. (2005) (34)
Evidence-based clinical practice : concepts and approaches (2000) (34)
Addressing the American health-care cost crisis: role of the oncology community. (2013) (34)
Estimated growth of lung volume reduction surgery among Medicare enrollees: 1994 to 1996. (1998) (34)
Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy (2011) (34)
Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials (2021) (34)
Examining the cost‐effectiveness of cancer screening promotion (2004) (34)
Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers. (2005) (34)
Completion of radiotherapy for local and regional head and neck cancer in medicare. (2002) (34)
New‐Onset Treatment‐Dependent Diabetes Mellitus and Hyperlipidemia Associated with Atypical Antipsychotic Use in Older Adults without Schizophrenia or Bipolar Disorder (2012) (33)
How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States. (2007) (32)
Cost Effectiveness of Gene Expression Profile Testing in Community Practice. (2018) (32)
Access to information sources and treatment considerations among men with local stage prostate cancer. (2009) (31)
A Decision-Analytic Evaluation of the Cost-Effectiveness of Family History–Based Colorectal Cancer Screening Programs (2010) (31)
How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. (2011) (30)
SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. (2011) (30)
Economic analysis of lung volume reduction surgery as part of the National Emphysema Treatment Trial. NETT Research Group. (2001) (29)
Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis (2009) (29)
Complementary and alternative medicine use among newly diagnosed prostate cancer patients (2010) (28)
Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare. (2015) (28)
Baseline Estimates of Adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health Insurer. (2015) (28)
The impact of using different imputation methods for missing quality of life scores on the estimation of the cost-effectiveness of lung-volume-reduction surgery. (2009) (28)
Medical costs associated with use of systemic therapy in adults with colorectal cancer. (2013) (27)
Evidence-based management: using serial firm trials to improve diabetes care quality. (2002) (27)
Health care costs among renal cancer patients using pazopanib and sunitinib. (2015) (27)
A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies (2018) (27)
A Pilot Study of a Comprehensive Financial Navigation Program in Patients With Cancer and Caregivers. (2020) (26)
Disenrollment From Medicaid After Recent Cancer Diagnosis (2008) (26)
The cost of adjuvant chemotherapy in patients with early‐stage breast carcinoma (2005) (25)
Improving early cycle economic evaluation of diagnostic technologies (2014) (24)
Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies (2012) (24)
Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens (2014) (23)
Structural incentives and adoption of medical technologies in HMO and fee-for-service health insurance plans. (1997) (23)
Relative Impact of Patient and Clinic Factors on Adherence to Primary Care Preventive Service Guidelines: An Exploratory Study (2001) (23)
Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings (2020) (23)
Family History Assessment to Detect Increased Risk for Colorectal Cancer: Conceptual Considerations and a Preliminary Economic Analysis (2005) (23)
Will Knowledge of Gene-Based Colorectal Cancer Disease Risk Influence Quality of Life and Screening Behavior? (2009) (23)
Role of bleeding recognition and evaluation in Black‐White disparities in endometrial cancer (2018) (23)
Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites (2010) (23)
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma (2016) (23)
Attitudes towards Genetic Screening for Predisposition to Colon Cancer among Cancer Patients, Their Relatives and Members of the Community (2003) (22)
A new model for reimbursing genome-based cancer care. (2014) (22)
Costs and Survival of Patients With Colorectal Cancer in a Health Maintenance Organization and a Preferred Provider Organization (2005) (22)
Cost - Effectiveness of Prophylactic AZT Following Neediestick Injury in Health Care Workers (1992) (22)
An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes (2012) (22)
Prioritization in Comparative Effectiveness Research: The CANCERGEN Experience (2012) (22)
Depression and Health Care Utilization at End of Life Among Older Adults With Advanced Non-Small-Cell Lung Cancer. (2018) (22)
Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer (2007) (21)
Paying for personalized care: Cancer biomarkers and comparative effectiveness (2012) (21)
Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population (2011) (21)
Discontinuation of Radiation Treatment among Medicaid‐Enrolled Women with Local and Regional Stage Breast Cancer (2010) (21)
Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial (2018) (21)
Cost-effectiveness of lung volume reduction surgery. (2008) (21)
Pharmacoeconomic Evaluations in the Treatment of Non-Small Cell Lung Cancer (2012) (21)
Recruiting adults with osteoarthritis into an aquatic exercise class: strategies for a statewide intervention. (1998) (20)
Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer. (2014) (20)
Critical Lessons From High-Value Oncology Practices (2017) (20)
Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group (2016) (20)
Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic (2021) (20)
Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs: Pick Your Poison. (2016) (19)
An ounce of prevention or a pound of cure? Investing to improve breast cancer outcomes for African American women. (2004) (19)
Systematic review of comparative effectiveness data for oncology orphan drugs. (2012) (19)
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. (2020) (19)
How Important is the Scientific Literature in Guiding Clinical Decisions?: The Case of Magnetic Resonance Imaging (1993) (18)
Breast cancer multigene testing trends and impact on chemotherapy use. (2016) (18)
Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? (2005) (18)
Stakeholder Perspectives on a Risk-Benefit Framework for Genetic Testing (2010) (18)
Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis (2019) (18)
Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report. (2020) (18)
Comparative Effectiveness of Robotically Assisted Compared With Laparoscopic Adnexal Surgery for Benign Gynecologic Disease (2014) (18)
Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim (2018) (17)
Information Seeking and Satisfaction with Information Sources Among Spouses of Men with Newly Diagnosed Local-Stage Prostate Cancer (2018) (17)
How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs. (2015) (17)
Weighing the Economic Evidence: Guidelines for Critical Assessment of Cost-Effectiveness Analyses (1999) (17)
Coronary artery bypass grafting in octogenarians: clinical and economic outcomes at community-based healthcare facilities. (2002) (17)
Tumor marker usage and medical care costs among older early-stage breast cancer survivors. (2015) (17)
Leverage, Default, and Mortality: Evidence from Cancer Diagnoses (2015) (17)
Cost effectiveness in practice and its effect on clinical outcomes (2014) (17)
Use of Oncotype DX in Women with Node-Positive Breast Cancer (2011) (17)
End-of-Life Services Among Patients With Cancer: Evidence From Cancer Registry Records Linked With Commercial Health Insurance Claims. (2017) (16)
Cancer diagnosis as a risk factor for personal bankruptcy. (2011) (16)
Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington state. (2013) (16)
A Review of Quality-of-Life Evaluations in Prostate Cancer (1999) (16)
Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care (2019) (16)
Systemic Therapy for Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in Nationally Representative US Claims Database (2013) (15)
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer. (2013) (15)
Observational study designs for comparative effectiveness research: an alternative approach to close evidence gaps in head-and-neck cancer. (2014) (15)
Novel Data Linkages to Characterize Palliative and End-of-Life Care: Challenges and Considerations. (2019) (15)
A Forensic Evaluation of the National Emphysema Treatment Trial Using the Expected Value of Information Approach (2008) (15)
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. (2014) (15)
Optimizing Sampling Strategies for Estimating Quality-adjusted Life Years (1997) (14)
Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models (2019) (14)
Managing the financial impact of cancer treatment: the role of clinical practice guidelines. (2012) (14)
How should we value lives lost to cancer? (2008) (14)
Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases (2014) (14)
Methods for reviewing economic evaluations of community preventive services: a cart without a horse? (2000) (14)
Patterns of blood product use among patients with myelodysplastic syndrome (2012) (14)
Complementary and alternative medicine use, patient-reported outcomes, and treatment satisfaction among men with localized prostate cancer. (2012) (13)
Localized prostate cancer: quality of life meets Whitmore's legacy. (2004) (13)
Colony‐Stimulating Factor Use and Impact on Febrile Neutropenia Among Patients with Newly Diagnosed Breast, Colorectal, or Non–Small Cell Lung Cancer Who Were Receiving Chemotherapy (2012) (13)
Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. (2015) (13)
A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. (2017) (12)
Effect of compensation method on the behavior of primary care physicians in managed care organizations: evidence from interviews with physicians and medical leaders in Washington State. (1998) (12)
Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer. (2015) (12)
Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer. (2019) (11)
Economic analyses and clinical practice guidelines why not a match made in heaven? (2002) (11)
Cost effectiveness of a program to promote screening for cervical cancer in the Vietnamese-American population. (2010) (11)
Body mass index and cancer screening in older American Indian and Alaska Native men. (2009) (11)
Chronic obstructive pulmonary disease: is there a case for early intervention? (2004) (11)
Implementing Lung Cancer Screening Using Low-Dose Computed Tomography: Recommendations From an Expert Panel. (2015) (11)
Resource utilization, cost, and health status impacts of coronary stent versus "optimal" percutaneous coronary angioplasty: results from the OPUS-I trial. (2002) (11)
Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach. (2012) (11)
Unanticipated and underappreciated outcomes during management of local stage prostate cancer: a prospective survey. (2010) (10)
Coronary artery bypass grafting in Native Americans: a higher risk of death compared to other ethnic groups? (2001) (10)
Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. (2012) (10)
Low-dose computed tomography lung cancer screening in the Medicare program: Projected clinical, resource, and budget impact. (2014) (10)
The Effects of Health Insurance on Access to New Medical Technologies (1997) (10)
Performance goals for an adjunct diagnostic test to reduce unnecessary biopsies after screening mammography: analysis of costs, benefits, and consequences. (2013) (10)
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting. (2013) (10)
Financial Toxicity: A Growing Concern Among Cancer Patients in the United States (2014) (10)
Implementation of comparative effectiveness research in personalized medicine applications in oncology: current and future perspectives (2015) (9)
Can Administrative Data Identify Incident Cases of Colorectal Cancer? A Comparison of Two Health Plans (2004) (9)
First-, second- and third-line lung cancer treatment patterns and associated costs in a US healthcare claims database (2015) (9)
Evaluating Evidence From A Decision Analysis (1999) (9)
Comorbidity is associated with higher risk of financial burden in Medicare beneficiaries with cancer but not heart disease or diabetes (2019) (9)
Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. (2012) (9)
Conduct disorder, war zone stress, and war-related posttraumatic stress disorder symptoms in American Indian Vietnam veterans. (2007) (9)
Oncologist and organizational factors associated with variation in breast cancer multigene testing (2017) (9)
Patient Recruitment Methods to Evaluate Treatment Decision Making for Localized Prostate Cancer (2010) (8)
Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing. (2019) (8)
Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA (2019) (8)
Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. (2013) (8)
Costs of potentially preventable emergency department use during cancer treatment: A regional study. (2017) (8)
Drug Price Inflation and the Cost of Assisted Death for Terminally Ill Patients-Death With Indignity. (2017) (8)
Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research (2012) (8)
Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities. (2017) (8)
Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer (2022) (8)
The forest and the trees: the human costs of cancer. (2007) (8)
OT1-03-01: A Randomized Phase III Clinical Trial of Standard Adjuvant Endocrine Therapy +/− Chemotherapy in Patients (pts) with 1–3 Positive Nodes, Hormone Receptor (HR)-Positive and HER2−Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: SWOG S1007. (2011) (8)
Economics and the new generation of targeted therapies for non-small cell lung cancer. (2010) (8)
What Happens When Imatinib Goes Generic? (2016) (8)
Validity of Natural Language Processing for Ascertainment of EGFR and ALK Test Results in SEER Cases of Stage IV Non-Small-Cell Lung Cancer. (2019) (7)
Imaging Techniques for Treatment Evaluation for Metastatic Breast Cancer (2014) (7)
Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105. (2019) (7)
Using electronic health record data to identify comparator populations for comparative effectiveness research (2020) (7)
Best practices for economic analysis alongside clinical trials: an ISPOR RCT–CEA Task Force report (2004) (7)
Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical trials. (2019) (7)
Coronary artery bypass grafting in Native Americans (2001) (7)
Does economics matter when treating advanced non-small cell lung cancer? (2002) (7)
The Outcomes of The Cancer Outcomes Research Symposium: A Commentary (2002) (7)
Preferences for Prostate Cancer Outcomes: A Comparison of the Patient Perspective, the General Population Perspective, and a Population at Risk for Prostate Cancer. (2016) (7)
Cancer-Directed Therapy and Hospice Care for Metastatic Cancer in American Indians and Alaska Natives (2015) (7)
Use of Epidermal Growth Factor Receptor Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer to Determine Erlotinib Use as First-Line Therapy (2011) (7)
Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non-small-cell Lung Cancer Treated in the Real-World. (2021) (7)
Cost–effectiveness of prostate cancer chemoprevention among high-risk men (2010) (7)
Health care use and primary prophylaxis with colony-stimulating factors. (2011) (7)
Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer. (2014) (7)
The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA (2022) (7)
From DNA to the Community (2000) (6)
Erratum: Promoting quality and evidence-based care in early-stage breast cancer follow-up (Journal of the National Cancer Institute (2014) 106:4 (dju034) DOI: 10.1093/jnci/dju034) (2014) (6)
What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia? (2018) (6)
Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials (2018) (6)
Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC) (2007) (6)
The cost of relapse in Hodgkin lymphoma. (2014) (6)
Physician Ordering of Screening Ultrasound: National Rates and Association With State-Level Breast Density Reporting Laws. (2019) (6)
Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. (2013) (6)
Cancer Stage in American Indians and Alaska Natives Enrolled in Medicaid. (2016) (6)
Health Economics Tools and Precision Medicine: Opportunities and Challenges (2020) (6)
Utility Estimates of Disease-Specific Health States in Prostate Cancer from Three Different Perspectives (2017) (6)
A comparison of approaches for association studies of polymorphisms and colorectal cancer risk (2012) (6)
Assessing the equality of means of healthcare costs (2003) (6)
Association of Pre-Existing Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients (2008) (5)
Basket Cases: How Real-World Testing for Drugs Approved Based on Basket Trials Might Lead to False Diagnoses, Patient Risks, and Squandered Resources. (2019) (5)
A Guideline for the Use of Pharmacoeconomic Models of Diabetes Treatment in the US Managed-Care Environment (2012) (5)
Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study (2018) (5)
Cost-Effectiveness Assessment of Brentuximab Vedotin to Prevent Progression Following Autologous Stem Cell Transplant in Hodgkin Lymphoma in the United States (2014) (5)
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer (2020) (5)
Perceptions on Barriers and Facilitators to Colonoscopy Completion After Abnormal Fecal Immunochemical Test Results in a Safety Net System (2021) (5)
Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non-Small-Cell Lung Cancer. (2020) (5)
Geographic distribution and survival outcomes for rural cancer patients treated in clinical trials. (2018) (5)
Parameter solicitation for planning cost effectiveness studies with dichotomous outcomes. (2001) (5)
Socioeconomic deprivation and cancer outcomes in patients treated in clinical trials. (2019) (5)
PCN7 THE COST-EFFECTIVENESS OF CAPECITABINE AS ADJUVANT ORAL CHEMOTHERAPY FOR DUKE'S C COLON CANCER (2005) (5)
ECONOMIC EVALUATION OF DIAGNOSTIC LOCALIZATION FOLLOWING BIOCHEMICAL PROSTATE CANCER RECURRENCE (2014) (5)
Access to the Indian Health Service Care System Is Not Associated with Early Enrollment in Medicaid for American Indian and Alaska Natives with Cancer (2013) (5)
Patient Reported Outcomes and Long-Term Non-Adherence to Aromatase Inhibitors. (2021) (5)
Weighing Costs and Benefits in the Economics of Cancer Care. (2019) (5)
What do we want from our investment in cancer research? (2005) (5)
Aspirin, clopidogrel, or both for secondary prevention of coronary disease. (2003) (5)
S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. (2022) (5)
Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials (2020) (5)
Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State. (2020) (4)
Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting. (2015) (4)
Association of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. (2008) (4)
28: The Cost-Effectiveness of Combined Androgen Blockade with Bicalutamide and LHRH Agonist in Men with Stage D2 Prostate Cancer (2005) (4)
Gut Check: Can Cost-Effectiveness Analysis Help Eliminate Gastric Cancer in Asia? (2007) (4)
263PSurvival gains from advances in first-line systemic therapy for HER2-positive metastatic breast cancer in the U.S., 1995-2015 (2017) (4)
Improving quality of care in oncology through healthcare payment reform. (2018) (4)
Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer (2016) (4)
The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making (2021) (4)
Patterns of Surveillance Advanced Imaging and Serum Tumor Biomarker Testing Following Launch of the Choosing Wisely Initiative. (2019) (4)
Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras. (2021) (4)
Computed Tomography Screening for Lung Cancer: A High-Value Proposition? (2016) (4)
Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up. (2020) (4)
The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations (2018) (4)
COST-EFFECTIVENESS OF METHYLATED SEPTIN 9 DNA VS. CURRENT STRATEGIES (2013) (4)
Incorporating economic analysis into clinical practice guidelines: a guide for hopeful users (2002) (4)
Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims (2019) (4)
Proposal to reimburse occupational medicine disease and injury claims through third party health insurance. (1994) (4)
Treatment patterns, mortality, and costs of care in unfit patients (pts) with relapsed chronic lymphocytic leukemia (CLL). (2014) (3)
Lung transplantation [2] (1998) (3)
Analysis of reimbursement (R) for next generation sequencing (NGS) on patients' tumors in the context of a personalized medicine program. (2017) (3)
Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment (2020) (3)
Effect of high patient out-of-pocket (OOP) cost for oral tyrosine kinase inhibitors (TKIs) on survival in EGFR and ALK positive stage IV non-small cell lung cancer (NSCLC). (2019) (3)
Financial burden at end of life: Findings from interviews with caregivers of patients with cancer. (2018) (3)
Validation of natural language processing (NLP) for automated ascertainment of EGFR and ALK tests in SEER cases of non-small cell lung cancer (NSCLC). (2017) (3)
Economic Issues and Genomic Medicine (2010) (3)
Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD. (2020) (3)
Health insurer policies toward risk-stratified colorectal cancer screening: a survey of health plan medical directors. (2012) (3)
Operationalizing a Rideshare Intervention for Colonoscopy Completion: Barriers, Facilitators, and Process Recommendations (2022) (3)
Incorporating comparative effectiveness research study endpoints into the treatment for positive-node, endocrine-responsive breast cancer (RxPONDER) study. (2011) (3)
Technology Assessment of Medical Devices (1998) (3)
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. (2017) (3)
Association of baseline cardiovascular risk factors and health care utilization and costs in elderly breast cancer patients enrolled in SWOG clinical trials. (2019) (3)
PCN14 IS COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE COST-EFFECTIVE COMPARED WITH COMBINED ANDROGEN BLOCKADE WITH FLUTAMIDE? (2005) (3)
Economic Evaluation of Systemic Treatments for Cytomegalovirus Retinitis in Patients with AIDS (2012) (3)
Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer (2019) (3)
PND1 CLINICAL AND PHARMACY UTILIZATION OUTCOMES WITH BRAND TO GENERIC ANTIEPILEPTIC UTILIZATION IN PATIENTS WITH EPILEPSY (2010) (2)
Comparative assessment for medications and devices: apples and oranges? (2010) (2)
29th Annual Meeting • American Society of Preventive Oncology San Francisco, CA • March 13–15, 2005 (2005) (2)
CHAPTER 36 – Economic Issues and Genomic Medicine (2009) (2)
Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials. (2020) (2)
A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancer. (2020) (2)
Economic Impact of Imaging Overutilization in Cancer Care. (2020) (2)
The role of chronic disease in the costs of potentially preventable emergency department use during treatment: A regional study. (2017) (2)
Costs and resource utilization associated with skeletal related events in Medicare patients with prostate cancer metastatic to bones. (2015) (2)
A pilot study of a comprehensive financial navigation program in cancer survivors. (2017) (2)
Cost-effectiveness of multi-gene panel sequencing (MGPS) for advanced non-small cell lung cancer (aNSCLC) patients. (2018) (2)
Cumulative incidence of financial hardship in metastatic colorectal cancer (mCRC) patients (pts): Primary endpoint results for SWOG S1417CD. (2020) (2)
PRM126 - A COMPARISON OF MIXTURE CURE AND STANDARD PARAMETRIC MODELING TO ESTIMATE LONG-TERM SURVIVAL FOR SMALL-CELL LUNG CANCER IN PATIENTS TREATED WITH NIVOLUMAB AFTER PROGRESSION (2018) (2)
What Is Cancer Outcomes Research?: A Diversity of Perspectives for an Emerging Field (2002) (2)
Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105). (2020) (2)
PID3: ECONOMIC EVALUATION OF SYSTEMIC TREATMENTS FOR CMV RETINITIS IN PERSONS WITH AIDS IN SWITZERLAND (1999) (2)
Lessons From Reporting National Performance Measures in a Regional Setting: Washington State Community Cancer Care Report. (2018) (2)
Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer. (2021) (2)
Abstract PD10-08: Baseline patient reported outcomes predict aromatase inhibitor adherence failure among women in enrolled in a randomized trial of text-messaging (2020) (2)
Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer. (2012) (2)
Stage at cancer diagnosis during the COVID-19 pandemic in western Washington state. (2021) (2)
Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients (2016) (2)
Costs Associated with Health Care Resource Use in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Treatment with Pazopanib Versus Sunitinib (2014) (2)
Comparing quality of care for Medicaid and commercially insured patients with cancer in Washington State. (2018) (2)
Estimated Cost-Effectiveness of Brentuximab Vedotin Vs. Best Supportive Care Following Autologous Stem Cell Transplant in Hodgkin's Lymphoma (2015) (2)
Is obinutuzumab cost-effective in the first-line treatment of CLL? (2014) (2)
Abstract A81: Relationship between out-of-pocket cost and use of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia (2016) (2)
Long-term consequences of intermittent and continuous androgen deprivation in older patients with metastatic prostate cancer. (2015) (2)
Disparity in telehealth and emergency department use among Medicaid and commercially insured patients receiving systemic therapy for cancer in Washington State following the COVID-19 Pandemic. (2021) (2)
A landscape analysis and discussion of value of gene therapies for sickle cell disease (2022) (2)
Effect of Clinical Trial Participation on Costs to Payers in Metastatic Non-Small-Cell Lung Cancer. (2021) (2)
Cancer Care of American Indians and Alaska Natives and Other Racial Groups Enrolled in Public and Private Insurance Plans (2010) (2)
Feasibility of Measuring Preferences for Chemotherapy Among Early-Stage Breast Cancer Survivors Using a Direct Rank Ordering Multicriteria Decision Analysis Versus a Time Trade-Off (2020) (2)
Estimating the costs and cost-effectiveness of promoting mammography screening among US-based Latinas. (2020) (2)
Treatment patterns, mortality, and health care utilization and costs in indolent non-Hodgkin lymphoma patients with relapsed or refractory disease. (2014) (2)
An Editorial on Tailoring Patient-Reported Outcomes to the Individual Patient: Precision PROs (2020) (1)
Patterns in provider types and cost of surveillance testing in early-stage breast cancer patients: A regional study. (2017) (1)
Abstract 5607: Risk of Re-hospitalization for Patients Using Clopidogrel With a Proton Pump Inhibitor (2009) (1)
MHC1 A Model of Primary Care Treatment of Major Depressive Disorder (1998) (1)
PCN190 Budget Impact of the DiviTum®Tka Assay in Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer (2021) (1)
RACE AND SHARED DECISION MAKING AMONG PROSTATE CANCER PATIENTS, FAMILY MEMBERS AND PHYSICIANS (2009) (1)
History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials. (2017) (1)
The cost of adverse events in metastatic breast cancer in taxane- and capecitabine-based regimens. (2013) (1)
Comparative Effectiveness of Robotically Assisted Compared With Laparoscopic Adnexal Surgery for Benign Gynecologic Disease (2015) (1)
Value of information analyses for real-time prioritization decisions within a cancer clinical trials cooperative group. (2015) (1)
Variability of Inotropic and Chronotropic Response During Dobutamine Stress Echocardiography and Possible Implications for Diagnostic Accuracy (2003) (1)
Conflicting Evidence Surrounding the Clopidogrel and Proton Pump Inhibitor Drug Interaction—Reply (2010) (1)
PMD38 Cost Minimization Analysis of a Multi-Site Randomized Clinical Trial of Home-Based Versus Laboratory-Based Testing for the Diagnosis and Treatment of Obstructive Sleep Apnea (HomePAP Study) (2012) (1)
Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. (2020) (1)
Baseline cancer worry and tumor marker testing among earlier-stage breast cancer patients participating in a Choosing Wisely pilot. (2020) (1)
Colony stimulating factor use and outcomes for breast, lung, and colorectal cancer patients in Washington State (2007) (1)
YIA19-001: Mechanisms of Diagnostic Delay Among Black women With Endometrial Cancer (EC): Results from Qualitative Interviews and a National Analysis of Healthcare Data (2019) (1)
Cost effectiveness of lung volume reduction surgery. (2003) (1)
Racial disparities in access to prostate cancer clinical trials: A county-level analysis. (2021) (1)
Projected Clinical, Resource, and Budget Impact of Implementing Low-Dose Computed Tomography Lung Cancer Screening in the United States (2014) (1)
Prevalence of Pedigrees Suggestive of Hereditary Nonpolyposis Colorectal Cancer among a Community Sample of Women Eligible for Screening Mammography (2000) (1)
The Potential Clinical, Resource Use, And Fiscal Impacts of Lung-Rads To Inform Lung Cancer Screening In Medicare (2016) (1)
An economic analysis alongside a prospective randomized multicenter clinical trial of Cisplatin/Vinorelbine vs. Carboplatin/Paclitaxel for advanced nons mall cell lung cancer (2000) (1)
Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis (2020) (1)
Healthcare Charges and Use in Commercially Insured Children Enrolled in Managed Care Health Plans in Washington State (2000) (1)
EPR22-119: Cost-Effectiveness of Multi-Cancer Early Detection (MCED) Test in Subgroups With Smoking History or Obesity (2022) (1)
PMH13 Developing a Task‐Based Instrument to Measure Migraine‐Related Productivity (1998) (1)
Screening for Colorectal Cancer With a Blood Test: Projected Effectiveness and Cost-Effectiveness of a Novel Plasma Methylated Septin-9 DNA (mSEPT9) Assay (2011) (1)
Racial Disparities in Access to Prostate Cancer Clinical Trials: A County-Level Analysis (2021) (1)
Prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204. (2018) (1)
Patient engagement on claims-registry reports of cost and quality. (2017) (1)
Cost-effectiveness of lung volume reduction surgery (2008) (1)
Cancer diagnosis and adverse financial events: Evidence from credit reports. (2021) (1)
PCN9 VALUE OF RESEARCH ANALYSES IN RESEARCH PRIORITIZATION OF CANCER GENOMIC APPLICATIONS (2011) (1)
Cost-effectiveness of a biopsy-based 8-protein prognostic assay to optimize treatment decisions in intermediate-risk early-stage prostate cancer. (2015) (1)
Health State Utilities Values For Post-Menopausal Women From The Women's Health Initiative Estrogen+Progestin Clincial Trial (2013) (1)
Barriers associated with inadequate follow-up of abnormal fecal immunochemical test results in a safety-net system: A mixed-methods analysis (2022) (1)
Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion (2017) (1)
Incentivizing Value In Managed Care Drug Formularies: Design, Implementation, And First-Year Outcomes Of A Value-Based Formulary (2014) (1)
Value in cancer care: Regional initiative to improve care through data reporting and interventions. (2016) (1)
Lung transplantation (1998) (1)
Using cancer registry records linked with health insurance records to measure costs and services at end-of-life. (2016) (1)
Medical care and bankruptcy: the author replies. (2013) (1)
Quality of life EQ-5D results from the AETHERA trial: A phase III study of brentuximab vedotin consolidation following autologous stem cell transplant for HL. (2015) (1)
PCN50 First and Second Line Lung Cancer Treatment Utilization Patterns and associated Costs in A United States Health Care Claims Database (2011) (1)
Effect of the COVID-19 Pandemic on Place of Death Among Medicaid and Commercially Insured Patients With Cancer in Washington State (2022) (1)
Lung cancer screening with low-dose computed tomography. (2013) (1)
P3.07-013 Determining EGFR and ALK Status in a Population-Based Cancer Registry: A Natural Language Processing Validation Study: Topic: Other – Geographical Differences (2017) (1)
Comparison of Treatment, Cost, and Survival in Patients With Metastatic Colorectal Cancer in Western Washington, United States, and British Columbia, Canada. (2020) (1)
Investing in Health (one Prescription at a Time): Out-of-pocket Spending For Medical Care (2006) (1)
The cost of treatment-related adverse events in metastatic breast cancer therapy: Taxanes versus capecitabine. (2013) (1)
Estimating Long-Term Survival for Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy: A Comparison of Standard and Mixture Cure Models (2018) (1)
Reassessing the Cost-effectiveness of Lung Transplantation: To the Editor (1996) (1)
Treatment, mortality, and health care costs in a U.S. cohort of indolent non-Hodgkin lymphoma patients with relapsed or refractory disease. (2014) (1)
Impact of skeletal-related events on survival in patients with prostate cancer metastatic to bones. (2015) (1)
Results of a pilot study to increase adherence to ASCO G-CSF recommendations at community clinics. (2020) (1)
Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (mCRC). (2019) (1)
Evidence-based clinical practice (2015) (1)
Out of system (OOS) costs for oncology clinics treating patients with breast, colorectal, and non-small cell lung cancer in Washington state. (2017) (0)
Impact of clinic characteristics on the adoption of a guideline-based standing order algorithm and patient accrual in the pragmatic cluster-randomized trial SWOG S1415CD (NCT02728596). (2018) (0)
Hepatic transplants. Liver transplantation: an OR nurse's perspective. (1992) (0)
Depression and Health Care Utilization at End-of-Life Among Older Adults with Non-Small Cell Lung Cancer (TH320D) (2017) (0)
Metastatic colorectal cancer (mCRC) treatment patterns in the Medicare population. (2018) (0)
Predicting low accrual in the Clinical Trials Cooperative Group Program’s phase II/III oncology trials. (2015) (0)
Treatment patterns of metastatic colorectal cancer (mCRC) in commercially-insured populations in Washington state. (2017) (0)
Survival benefits of second-line chemotherapy in metastatic castrate-resistant prostate cancer (CRPC) in a southeastern oncology community practice. (2012) (0)
Measuring baseline adherence to Choosing Wisely recommendations in regional oncology clinics: Challenges and strategies. (2014) (0)
The value of research for ERCC1 expression testing to inform adjuvant chemotherapy decisions in resected Stage II non-small cell lung cancer. (2011) (0)
Use and findings of K-ras in colorectal cancer (CRC) testing in administrative and electronic medical records (EMR) data from 2005 through 2010. (2012) (0)
Impact of Value-Based Benefits on Use of and Adherence to Drugs in 3 Disease Cohorts (2015) (0)
Cost effectiveness of reduced intensity conditioning and transplantation of unrelated umbilical cord blood versus HLA haploidentical related bone marrow for adults with hematologic malignancies. (2022) (0)
VV2 DESIGN AND VALIDATION OF A NEW WEB-BASED STANDARD GAMBLE INTERVIEW (2003) (0)
List of Excluded Published Literature Studies (2014) (0)
Risk Prediction of Hepatitis B or C or HIV Among Newly Diagnosed Cancer Patients. (2023) (0)
Abstract P6-12-09: Association between cardiovascular risk factors and cardiac events among breast cancer patients enrolled in SWOG clinical trials (2018) (0)
Case-control studies of cancer surveillance procedures. (2011) (0)
EE3 IS NICE TOO NASTY? A COMPARISON OF ANTICANCER DRUG COVERAGE DECISIONS IN THE UNITED STATES AND UK (2009) (0)
Health care utilization and costs at end of life among patients with leukemia or lymphoma in a regional cancer registry-insurance claims linked database. (2016) (0)
OA07.06 Patient Knowledge and Expectations Related to Return of Genomic Results in the Lung-MAP (SWOG 1400) Biomarker-Driven Clinical Trial (2019) (0)
PCN26 FIRST-, SECOND- AND THIRD-LINE CHEMOTHERAPY FOR NONSMALL CELL LUNG CANCER: PATTERNS OF CARE AND COST (2007) (0)
Cost effectiveness: Con (2002) (0)
Survival patterns by line of treatment of stage IV colorectal (CRC) patients from local U.S. oncology practice. (2012) (0)
Washington State Community Cancer Care Report: Implications for value-based purchasing. (2018) (0)
PCN93 COST-EFFECTIVENESS OF MULTI-GENE PANEL SEQUENCING FOR PATIENTS WITH ADVANCED MELANOMA (2019) (0)
Development of cancer care episodes to measure costs for breast, colorectal, and non-small cell lung cancer. (2017) (0)
Real-world outcomes with immuno-oncology (IO) therapies: A prospective, observational cohort study in patients (pts) with advanced melanoma (OPTIMIzE). (2019) (0)
The Washington State Community Cancer Care Report: A multi-stakeholder effort to characterize quality of care and costs for Washington State oncology practices. (2018) (0)
Performance Goals for an Adjunct Diagnostic Test to Reduce Unnecessary Biopsies After Screening Mammography: Analysis of Costs, Benefits, and Consequences. (2016) (0)
Economic Analyses alongside Cancer Clinical Trials (2012) (0)
PRO13 Economic IMPACT of Sickle Cell Disease, Treatments, and Related Complications (2021) (0)
Information Seeking and Satisfaction with Information Sources Among Spouses of Men with Newly Diagnosed Local-Stage Prostate Cancer (2017) (0)
Abstract 2767: Consistency of standing orders for primary prophylactic CSF within a national network of community oncology practices: SWOG intergroup trial S1415CD (2017) (0)
Survival patterns by line of treatment of stage IIIb/v NSCLC patients from community U. S. oncology practice. (2012) (0)
Risk Factors for Febrile Neutropenia among Breast, Lung, and Colorectal Cancer Patients: A Retrospective Analysis of Health Plan Databases (2008) (0)
PCN153 A Trial for Evaluating Breast Cancer Tumor Marker Use Impact: A Value of Research Analysis (2012) (0)
Use of real-world data to understand barriers to interventional clinical trial enrollment in community oncology clinics (COC). (2020) (0)
Provider mix and costs associated with treatment of patients with bone metastases secondary to prostate cancer. (2012) (0)
Measuring adherence to a Choosing Wisely recommendation in a regional oncology clinic. (2016) (0)
Cure Models: Accounting For Cured Patients In Economic Evaluations (2015) (0)
Patterns of care and survival trends in elderly metastatic colorectal cancer patients: A SEER-Medicare analysis. (2011) (0)
PCN10 ARE FURTHER STUDIES OF BREAST CANCER TUMOR MARKERS TO DETECT RECURRENCE WORTHWHILE? A VALUE OF RESEARCH ANALYSIS (2011) (0)
Receipt of Screening Mammography by Insured Women Diagnosed With Breast Cancer and Impact on Outcomes. (2021) (0)
PCN11 COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL THERAPY FOR NON-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER (2006) (0)
The potential clinical and fiscal impacts of blood-based methylated Septin9 testing for colorectal cancer screening. (2016) (0)
Translating an Economic Analysis into a Tool for Public Health Resource Allocation in Cancer Survivorship (2023) (0)
Polypharmacy and medication costs at end of life among commercially insured adults age 65 and older with cancer. (2018) (0)
Feasibility And Acceptability Of Minimal Modeling Value Of Information Analyses For Real-Time Prioritization Decisions Within A Large Cancer Clinical Trials Cooperative Group (2015) (0)
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Metastatic Prostate Cancer Patients (2016) (0)
34: Bladder Cancer Treatment in the Medicare Population: Predictors of Intravenous Chemotherapy and Cystectomy (2006) (0)
CE3 THE COSTS OF ADJUVANT CHEMOTHERAPY IN EARLY STAGE BREAST CANCER PATIENTS: COMPARISON OF ATTRIBUTABLE COST AND MICROCOSTING APPROACHES (2004) (0)
Can Effective Cancer Care Become Affordable Again (2012) (0)
A Retrospective Evaluation of Radiation Therapy Treatment Patterns among Medicare Enrollees with Head and Neck Cancer (2008) (0)
Polypharmacy, chemotherapy receipt, and medication-related out-of-pocket costs at end of life among commercially insured adults with advanced cancer (2021) (0)
PCN158 LUXEMBOURG LUNG CANCER PROJECT: POTENTIAL CLINICAL AND ECONOMIC IMPACT OF BIOMARKER DEVELOPMENT IN THE DIAGNOSIS AND TREATMENT OF SINGLE PULMONARY NODULES IN LUXEMBOURG (2009) (0)
Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer. (2022) (0)
Trends in Expenditures for Oral Chemotherapy after Market Entry (2007-2013) (2016) (0)
Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204 (2022) (0)
Systemic Therapy for Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in Nationally Representative US Claims Database (2013) (0)
Evaluating the feasibility of using an electronic patient-reported outcome (ePRO) smartphone application (app) and biosensor by patients with cancer undergoing systemic treatments. (2022) (0)
Patterns of surveillance testing in commercially insured patients with breast cancer across provider types: A regional study. (2017) (0)
PCN15 A Longitudinal Review of Treatment Patterns in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) From Community Practice in the United States (2012) (0)
Cost-Effectiveness of a Biopsy-Based 8-Protein Prognostic Assay to Optimize Treatment Decisions In Gleason 3+3 And 3+4 Prostate Cancer (2015) (0)
PCN17 Chemotherapy Treatment and Impact of Second Line Chemotherapy on Overall Survival (OS) in Metastatic Castrate Resistant Prostate Cancer (CRPC) in Southeastern Oncology Community Practice (2012) (0)
Stakeholder-informed "Choosing Wisely" implementation project in regional oncology clinics. (2013) (0)
Impact of rurality versus neighborhood deprivation on stage at diagnosis and survival: A regional analysis. (2019) (0)
Abstract PL03-04: Challenges in using genetic information and family history in primary care (2010) (0)
Effects of a Guideline-Informed Clinical Decision Support System Intervention to Improve Colony-Stimulating Factor Prescribing (2022) (0)
Summary of Key Informant Interviews (2014) (0)
Trends in health-related quality of life (HRQoL) and income over time in older adults with and without cancer: Evidence from the Surveillance, Epidemiology, and End Results–Medicare Health Outcomes Survey (SEER–MHOS) linked database. (2014) (0)
PCN55 Total Health Care Expenditures in Newly Diagnosed Colorectal Cancer Adults With Private Insurance in a Claims Database in the United States (2012) (0)
Survival trends and patterns of chemotherapy use in elderly metastatic colorectal cancer (mCRC) patients. (2011) (0)
A pragmatic cluster-randomized trial of a standing physician order entry intervention for colony stimulating factor use among patients at intermediate risk for febrile neutropenia (SWOG S1415CD). (2022) (0)
Ambulatory and Office UrologyReply (2009) (0)
Using deep learning with registry linked claims data to predict hospitalization during chemotherapy: Feasibility study. (2019) (0)
PCN53 RISK OF PERSONAL BANKRUPTCY FOLLOWING A CANCER DIAGOSIS (2011) (0)
Intervention non-adherence in a pragmatic randomized trial of a standardized order entry for colony stimulating factor prescribing. (2022) (0)
PCN136 COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AMONG LOCAL STAGE PROSTATE CANCER PATIENTS: TYPES, FACTORS ASSOCIATED WITH USE AND PERCEIVED BENEFITS (2009) (0)
O-96 Use of and outcomes from adjuvant therapy in early stage nonsmall cell lung cancer: evidence from SEER-Medicare (2003) (0)
Regional engagement to define, report, and use quality metrics to improve palliative care in oncology. (2016) (0)
A pilot study to increase adherence to ASCO Choosing Wisely recommendations for breast cancer surveillance at community clinics. (2020) (0)
PCN74 WILL KNOWLEDGE OF GENETIC RISK FOR CANCER INFLUENCE QUALITY OF LIFE AND SCREENING BEHAVIOR? FINDINGS FROM A POPULATION-BASED STUDY (2008) (0)
A Maximum Entropy Model of Follow-up: Using Cancer Registry and Insurance Data to Identify Encounters for Breast Cancer Surveillance (2016) (0)
Creating Value-Based Metrics for Cancer Care: A Stakeholder-Informed, Evidence-Driven Approach (2015) (0)
A STUDY TO DETERMINE THE EFFECT OF ATHLETIC PARTICIPATION ON THE ACADEMIC PERFORMANCE, ATTENDANCE, AND DISCIPLINE OF HISPANIC STUDENTS (2010) (0)
The Authors Respond. (2015) (0)
PCN47 Medical Expenditures Associated With the Use of Systemic Therapy for Colorectal Cancer in Privately Insured Adults in a Claims Database in the United States (2012) (0)
Contents Vol. 2, 1999 (2000) (0)
Sa1022 – Racial Disparities in Colorectal Cancer Mortality: the Role of Endoscopy Wait-Time and Disease Stage (2019) (0)
PR3 PREFERENCE VALUES FOR HEALTH STATES ASSOCIATED WITH COLON CANCER AND ITS TREATMENT (2007) (0)
Trends in the geographic distribution of cancer clinical trials in the US: 2008-2015. (2017) (0)
Preferences For Prostate Cancer Outcomes: A Comparison Of Patient And General Population Perspectives (2014) (0)
Potential survival gains from first-line (1L) systemic therapy advances in metastatic triple-negative breast cancer (mTNBC). (2018) (0)
Costs to healthcare payers associated with clinical trial (CT) participation in metastatic non-small cell lung cancer (NSCLC). (2020) (0)
PCN89 RACE AND SHARED DECISION MAKING AMONG PROSTATE CANCER PATIENTS, FAMILY MEMBERS AND PHYSICIANS (2008) (0)
The association between American Indian/Alaska Native race and time to treatment initiation for nonmetastatic breast, colorectal, and lung cancer patients in Medicare. (2014) (0)
Evaluating the impact of a trial in breast cancer tumor markers: A value of research analysis. (2012) (0)
PCN266 ONCOLOGY SEQUENCE MODELS IN HEALTH TECHNOLOGY ASSESSMENT-A LITERATURE REVIEW (2020) (0)
Regional initiative to define, collect, and report value metrics in cancer care. (2014) (0)
Polypharmacy and out-of-pocket medication costs in the last month of life among commercially insured patients with advanced cancer: Insights from linking a regional cancer registry and insurance claims. (2017) (0)
Subject Index Vol. 2, 1999 (2000) (0)
Patient (pt) experience with a smartphone application (app) and biosensor for remote symptom monitoring during systemic cancer therapy: Qualitative findings from initial testing. (2022) (0)
PCN9 PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH SECONDARY PROPHYLAXIS FOR WOMEN WITH EARLYSTAGE BREAST CANCER RECEIVING CHEMOTHERAPY (2007) (0)
PCN75 WHAT CHOICES DO MEN FEEL THEY HAVE IN SELECTION OF PROSTATE CANCER TREATMENT (2007) (0)
Medicaid patients more likely to die at home without hospice during the pandemic versus before, exacerbating disparities with commercially insured patients. (2021) (0)
Over- And Underuse of Therapeutic and Palliative Care Services for Cancer Patients at End of Life: A Population-Based Study (2016) (0)
PCN11 Systemic Therapy for Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in Nationally Representative Claims Database in the United States (2012) (0)
Implementing an EHR guideline–based intervention in paper ordering systems. (2018) (0)
PCN145 A COMPARISON OF PHYSICIAN AND PATIENT DECISION MAKING FOR FIRST VERSUS SECOND OPINIONS AMONG MEN WITH LOCAL STAGE PROSTATE CANCER (2010) (0)
CASE2 INVENTING A TIERED FORMULARY BASED ON THE INCREMENTAL COST-EFFECTIVENESS OF DRUGS (2010) (0)
PMD6 DEVELOPMENT OF A WEB-BASED SURVEY TO DETERMINE PRACTICE PATTERNS FOR TREATMENT OF ADVANCED STAGE BREAST CANCER IN FIVE EUROPEAN COUNTRIES (2003) (0)
Predictors of delays in initiation of oral tyrosine kinase inhibitors (TKIs) in EGFR and ALK positive advanced non-small cell lung cancer (NSCLC). (2019) (0)
Cost implications of clinical trial (CT) participation in metastatic non-small cell lung cancer (NSCLC). (2020) (0)
A Structured Approach to Prioritizing Cancer Research Using Stakeholders and Value of Information (2018) (0)
Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD (2022) (0)
An Economic Analysis Of Workplace Screening For Obstructive Sleep Apnea (2014) (0)
A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life (2019) (0)
OA01.02 A Lung Cancer Surgical Mortality Risk-Prediction Algorithm to Inform Lung Cancer Screening Shared Decision-Making (2017) (0)
PCN2 LEAD TIME IN THE EVALUATION OF HISTORICAL SURVIVAL IMPROVEMENTS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (2005) (0)
Intensity of end-of-life (EOL) cancer care in Western Washington (WA) versus Alberta (AB), Canada (CA). (2019) (0)
Disparities In Risk Of Bankruptcy Among Patients Diagnosed With Cancer (2014) (0)
Proof or principle? On economic modeling to guide genomic testing in metastatic colorectal cancer. (2012) (0)
Development of cost and quality composites for the 2012 ASCO Choosing Wisely measures: Methods and evidence. (2015) (0)
Impact of value of research analyses on SWOG’s clinical trial capsule scoring. (2017) (0)
Economics of treatment guidelines for hypertension (1999) (0)
PCN44 HEALTH RELATED QUALITY OF LIFE EVALUATIONS IN PROSTATE CANCER: WHO'S BEING STUDIED? (2005) (0)
Abstract PL06-05: The cost effectiveness of patient navigation (2011) (0)
CN2 ECONOMIC EVALUATION OF EGFR-GUIDEDTREATMENT IN ADVANCED REFRACTORY NON SMALL-CELL LUNG CANCER (2008) (0)
PCN329 - OUTCOMES-BASED ARRANGEMENTS IN ONCOLOGY: A LANDSCAPE ANALYSIS (2018) (0)
Lung transplantation. (1998) (0)
A pilot study of a comprehensive financial navigation program in cancer patients and caregivers. (2019) (0)
Potential impact of clinical trial (CT) participation on survival of patients with metastatic non-small cell lung cancer (NSCLC). (2019) (0)
Predictors of advanced imaging use during breast cancer surveillance. (2017) (0)
Do rural cancer patients receive lower quality cancer care? Assessing the impact of rurality on oncology practice performance measures. (2019) (0)
Clinician-Based Performance Status and Its Correlation with Patient-Reported Outcomes: Findings from a Prospective Observational Study in Patients with Mantle Cell Lymphoma (2021) (0)
Comparing Ways to Improve Prescribing of Colony-Stimulating Factor in Cancer Treatment -- The TrACER Study (2022) (0)
PCN170 Can Early U.S. Adoption of Cancer Drugs Inform HTA Decision-Making? (2021) (0)
SurvivalandLifetimeCostsAssociatedWithFirst-LineBevacizumabUse in Older Patients With Metastatic Colorectal Cancer (2014) (0)
How do clinics perform across multiple end of life metrics (2017) (0)
Who gets a referral to oncologists and subsequent treatments for stages III and IV non-small cell lung cancer (NSCLC)? (2012) (0)
705P Systematic literature review (SLR) and network meta-analysis (NMA) of first-line (1L) therapies for locally advanced/metastatic urothelial carcinoma (la/mUC) (2021) (0)
PCN12 HORIZON SCANNING TO SUPPORT PRIORITY-SETTING FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS (2010) (0)
Feasibility and usability of an electronic patient (pt)-reported outcome (ePRO) smartphone application (app) and biosensor for pts with cancer undergoing systemic therapy. (2022) (0)
PCN7 TRENDS IN CHEMOTHERAPY USE, OUTCOMES, AND COST FOR PATIENTS WITH ADVANCED NONSMALL LUNG CANCER: EVIDENCE FROM SEER-MEDICARE (2004) (0)
Optimizing Cancer Clinical Trials Research Investment Decisions In The United States: A Proof Of Concept Portfolio Management Evaluation (2015) (0)
Abstract P3-03-05: The budget impact of the DiviTum®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer (2022) (0)
Erratum: Stakeholder assessment of the evidence for cancer genomic tests: Insights from three case studies (Genetics in Medicine (2012) 14 (656-662) DOI: 10.1038/gim.2012.3) (2013) (0)
Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (aNSCLC). (2018) (0)
Calculation of Estimate of Number of Women Receiving Imaging for Treatment Evaluation of Metastatic Breast Cancer (2014) (0)
The value of research for ERCC1 testing in stage I non-small cell lung cancer (NSCLC). (2011) (0)
The influence of patient engagement on the design and implementation of a clinical trial to improve cancer care delivery. (2018) (0)
PCN51 Comparing the Use and Cost of Radiopharmaceuticals in Prostate Cancer Patients With and Without Bone Metastasis (2012) (0)
MA22.02 The Impact of Patient Engagement on Study Design and Patient Recruitment in a Pragmatic Trial to Improve Cancer Care Delivery (2019) (0)
Economic Analysis of Screening, Diagnostic, and Treatment Technologies for Cancer: Reflections and a Roadmap for Prospective Authors. (2022) (0)
Critical Care Perspective End-of-Life Care in the Intensive Care Unit Can We Simultaneously Increase Quality and Reduce Costs? (2012) (0)
Care coordination and emergency department (ED) use at the end of life for patients with cancer: Findings from structured interviews with primary caregivers. (2018) (0)
Performance of a low-dose computed tomography (LDCT) lung cancer screening program: Findings from a registry study. (2014) (0)
List of Abstracted Published Literature Studies (2014) (0)
Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC) (2022) (0)
Reply. (2019) (0)
Economic Analysis of Screening, Diagnostic, and Treatment Technologies for Cancer: Reflections and a Roadmap for Prospective Authors. (2022) (0)
PCN54 Evaluating the Inpatient Hospitalization Costs of Treating Prostate Cancer Patients (2012) (0)
From A to Xeloda: Practical considerations for implementing a chemotherapy regimen ordering system intervention. (2018) (0)
Budget Impact of the 14-Gene Risk-Score (RS) Assay to Inform Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer (NSCLC) (2014) (0)
Insurance Coverage and Aid-in-Dying Medication Costs-Reply. (2017) (0)
Economics of Treatment Guidelines for Hypertension–Reply–I (1999) (0)
PMD5 Use and Findings of K-Ras in Colorectal Cancer (CRC) Testing in Administrative and Electronic Medical Records (EMR) Data from 2005 Through 2010 (2012) (0)
Comment on: Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. Author's reply (2002) (0)
PCN35 SYSTEMATIC REVIEW OF THE IMPACT OF CHEMOTHERAPY ON PATIENT REPORTED OUTCOMES IN ADVANCED NON-SMALL-CELL LUNG CANCER (2009) (0)
PCN242 REDEFINING VALUE IN ONCOLOGY: APPLICATION OF MIXTURE CURE MODELS FOR ECONOMIC ANALYSES OF NOVEL THERAPIES FOR SMALL CELL LUNG CANCER (SCLC) (2019) (0)
End of life services for cancer patients: A population-based evaluation. (2016) (0)
Clinic level variation in emergency department and inpatient utilization in a community setting. (2017) (0)
Patient and provider perceptions of emergency room visits during chemotherapy. (2019) (0)
Regional initiative to use data transparency to improve cancer care. (2016) (0)
Colorectal Cancer Screening with Blood-Based Biomarkers: Cost-Effectiveness of Methylated Septin 9 DNA versus Current Strategies Epidemiology,Biomarkers&Prevention (2013) (0)
Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada (2020) (0)
Cost-effectiveness and lifetime implications of using finasteride to reduce prostate cancer incidence and mortality. (2004) (0)
Feasibility of a digital medicine program in optimizing opioid pain control in cancer patients (SWOG S1916). (2020) (0)
Patterns of hospice use for metastatic cancer in the American Indian/Alaska Native and non-Hispanic white populations. (2014) (0)
PCN82 RESEARCH PRIORITIZATION FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS (2010) (0)
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD (2022) (0)
Measuring adherence to 2012 Choosing Wisely recommendations: SEER Registry linked with health plan data. (2014) (0)
Search Terms for Published Literature Review (2014) (0)
Adverse Events (AES) Associated with Bevacizumab (BV) In Older Patients (PTS) With Metastatic Colorectal Cancer (MCRC) (2012) (0)
P1.03-036 Adherence to Eligibility Criteria for Low-Dose CT Screening in an Academic Center (2017) (0)
Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada (2020) (0)
Putting the 'Economics' Back Into Health Economics Outcomes Research (2014) (0)
PMC2 A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF GENETIC TESTING TECHNOLOGIES (2005) (0)
Adverse events (AE) following diagnosis (Dx) in older metastatic colorectal cancer (mCRC) patients (Pts). (2012) (0)
Can order entry systems improve oncology practice? The TrACER Experience. (2022) (0)
Blood Product Use in Recently Diagnosed Persons with Myelodysplastic Syndrome: A Population Study. (2009) (0)
The Use of Superlatives in Cancer Research (2016) (0)
Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer (2021) (0)
A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia (2022) (0)
Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). (2021) (0)
Chapter 30 – Economic Burdens and Access to Care Barriers for the Older Cancer Patient (2012) (0)
PCN12 Survival Patterns by Line of Treatment of Stage IV Colorectal (CRC) Patients From Local Oncology Practice in the United States (2012) (0)
PCN53 Patterns of Care and Costs Associated With Treatment of Patients With Bone Metastases Secondary to Prostate Cancer (2012) (0)
Racial Disparities in Colorectal Cancer Mortality: the Role of Endoscopy Wait-Time and Stage at Diagnosis (2020) (0)
PCN41 Enhanced Cost-Effectiveness Analysis Using EHR Data for Real World Value (2021) (0)
Initial use of newer agents for advanced non-small cell lung cancer: Evidence from the National Cancer Institute Patterns of Care study. (2010) (0)
HICOR IQ: Developing a regional oncology metric reporting platform. (2016) (0)
Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants in SWOG clinical trials. (2016) (0)
Compiling and Reconciling Evidence to Assign Risk of Febrile Neutropenia to Chemotherapy Regimens (2016) (0)
P1.16-30 Impact of Patient TKI Copayments on Insurance Expenditure in Advanced EGFR or ALK Positive Non-Small Cell Lung Cancer (NSCLC) (2019) (0)
Potential cost-effectiveness of a diagnostic that identifies localized versus metastatic prostate cancer in men with biochemical recurrence after radical prostatectomy. (2013) (0)
6152 POSTER Trends in Survival and Chemotherapy (CTx) Usage in Elderly Patients With Metastatic Colorectal Cancer (mCRC) (2011) (0)
The expected value (EVPI and EVSI and EVIC) of a proposed clinical trial of patients with early-stage breast cancer. (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Scott David Ramsey?

Scott David Ramsey is affiliated with the following schools:

University of York
University of Michigan
University of California, Los Angeles
Wayne State University
University of Washington
Columbia University

Scott David Ramsey's Academic­Influence.com Rankings

Scott David Ramsey's Degrees

Why Is Scott David Ramsey Influential?

Scott David Ramsey's Published Works

Published Works

What Schools Are Affiliated With Scott David Ramsey?

Scott David Ramsey's AcademicInfluence.com Rankings